Eurofins Scientific Societe Europeenne

Eurofins Publishes Robust Method to Analyse SARS-CoV-2 in Wastewater Samples, Providing Early Warning of Potential COVID-19 Outbreak at a Given Site

A study undertaken by Eurofins scientists has resulted in a robust method to analyse SARS-CoV-2 in wastewater samples, allowing for early detection of virus presence at a given site, before the virus spreads too broadly or as a way to monitor the effectiveness of containment measures put in place.

As part of the study, Eurofins team of scientists used wastewater samples which had been collected during the COVID-19 pandemic in Denmark. They were able to detect the virus in a sample taken three days before patient 0 was identified in the country.

The findings of this study are particularly relevant for municipalities, production facilities, hospitals, nursing homes etc. At those sites, wastewater testing, offered as part of the Eurofins COVID-19 Sentinel™ programme, can give an early indication of the presence of SARS-CoV-2, therefore allowing for relevant containment measures in order to avoid an outbreak of the disease. With a growing understanding of the very significant role pre-symptomatic and asymptomatic virus carriers play in the pandemic, early detection of virus presence on a site is a vital first step to identifying the potential carrier(s) and putting increased measures in place to contain the disease. As the method developed by Eurofins is semi-quantitative, it also offers a strong tool to monitor the development of an outbreak over time and the efficacy of the containment measures put in place when an outbreak is detected.

This waste water testing method comes as yet another powerful tool in the Eurofins COVID-19 Sentinel™ suite of tests to help with the identification and containment of the COVID-19 pandemic. In real life over the last few weeks without requiring human testing, the Eurofins COVID-19 Sentinel™ programme has demonstrated its capacity to detect the presence of the SARS-CoV-2 virus on a site, before the affected employee had symptoms and knew of his/her infection.

The full release can be found at:

About Eurofins, the global leader in Bioanalysis

With over 47,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

EN
14/07/2020

Reports on Eurofins Scientific Societe Europeenne

Eurofins Scientific S.E: 1 director

A director at Eurofins Scientific S.E bought 6,000 shares at 56.855EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Bruno de La Rochebrochard
  • Bruno de La Rochebrochard

EUROFINS SCIENTIFIC: FY guidance again upgraded after strongest H1 res...

EUROFINS SCIENTIFIC - BUY | EUR125 FY guidance again upgraded after strongest H1 results Results again supported by Covid activities FY guidance again revised upwards

Bruno de La Rochebrochard
  • Bruno de La Rochebrochard

EUROFINS SCIENTIFIC: Q1 IMS: Trends that remain largely positive | BUY...

EUROFINS SCIENTIFIC - BUY | EUR125 Q1 IMS: Trends that remain largely positive Good start, ahead expectation Guidance which sounds to us still conservative

Bruno de La Rochebrochard
  • Bruno de La Rochebrochard

EUROFINS SCIENTIFIC - BUY | EUR125 FY results: Far beyond management e...

Largely exceed expectations Guidance revisited but sound to us conservative

Bruno de La Rochebrochard
  • Bruno de La Rochebrochard

EUROFINS SCIENTIFIC - BUY vs. NEUTRAL | EUR125

EUROFINS SCIENTIFIC - BUY vs. NEUTRAL | EUR125(+33%) Back to Buy recommendation after recent share price consolidation (contact) Good surprises to be expected in the short term… …and the medium term Strong financials allowing the group to remain on the look-out for all opportunities Buy vs Neutral after recent share price consolidation. TP of EUR125 confirmed

ResearchPool Subscriptions

Get the most out of your insights

Get in touch